Pfizer: encouraged by lung cancer drug dacomitinib study

(CercleFinance.com) - Pfizer released on Tuesday what it called "encouraging" results from a study evaluating dacomitinib as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with EGFR-activating mutations.


The trial showed a median overall survival of 34.1 months for patients receiving dacomitinib, representing over a seven-month improvement, compared to 26.8 months with AstraZeneca's Gefitinib.

The data was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Copyright (c) 2018 CercleFinance.com. All rights reserved.